SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back

: Challenges in Pulmonary and Critical Care 2018
Activity/Course #:
: 12.01.18PULM
: Free
Release/Start Date:
: Dec 01 2018
Expiration Date:
: Dec 01 2018
: Pulmonology
Target Audience:
: Pulmonologists, Hospitalists, Primary Care Providers
: Live Pulmonary Conference
Estimated Time To Complete CME Activity:
: 6.0 hours
: 6.0 AMA PRA Category I Credit(s)
6.0 AANP Contact hour(s)
Hardware/Software Requirements:

Saturday, December 1, 2018
Fort Lauderdale Marriott Coral Springs
11775 Heron Bay Blvd
Coral Springs, FL 33076
(954) 753-5598

Registration Fee

There is no registration fee for this activity.

Special Accommodations

NACE fully complies with the legal requirements of the Americans with Disabilities Act. Any activity registrant who feels s/he may need accommodations based on the impact of a disability should contact NACE to discuss your specific need.

Event Parking

Complimentary self-parking is available at the hotel.

Program Summary

The goal of this CME activity is to provide an update in the prevention, diagnosis and management of pulmonary disease to pulmonologists, hospitalists, primary care providers and other health care providers who treat patients with pulmonary diseases.  

We have recruited a faculty of well-known thought leaders and experienced teachers who, as clinicians themselves, understand the challenges you face every day as a healthcare provider. Our faculty will be at your disposal to provide evidence-based science, current treatment guidelines, discuss challenging cases, and provide answers for you that can ultimately lead to better health care for your patients. The presentations will include several interactive cases and discussion sessions to keep you actively learning.

Please join us and become an active participant in this one-day learning community of your peers.

Learning Objectives
At the conclusion of this program, participants should be able to:

1. Describe the newer concepts in the pathophysiology of asthma and type 2 inflammation, and the implications of biologic therapies in the era of precision medicine; Determine the utility of simple biomarkers to identify patients who are candidates for targeted biologic therapies and appropriate referral; Discuss the impact of comorbid conditions on asthma control and the evidence-based approach to their treatment; Discuss the paradigms of multidisciplinary care in asthma, with an emphasis on patient and provider education, to improve adherence to inhalers and emerging biologic therapies in asthma. 

2. Tailor COPD pharmacotherapy according to current recommended therapeutic strategies which incorporate unique patient needs and characteristics; Discuss strategies to facilitate the appropriate use of inhaled therapies for COPD, including the importance of proper inhaler technique; Recognize appropriate strategies to prevent and manage COPD exacerbations and to provide transitions of care post hospitalization; Collaborate with members of interprofessional health care team to create an effective patient-centered, COPD chronic disease management program.

3. Explain the importance of early identification and differentiation of interstitial lung diseases (ILDs); Describe the diagnostic approach for ILD, and when to refer patients to ILD centers; Discuss the management of idiopathic pulmonary fibrosis (IPF), including its risk factors and comorbidities; Recognize the role of patient education for effective management of ILD.

4. Discuss the pathophysiology of AAT deficiency (AATD) and its impact on chronic obstructive pulmonary disease (COPD) risk; Interpret the clinical significance of laboratory test results for AATD; Discuss treatment options for AATD and latest GOLD guideline recommendations; Discuss strategies to enhance detection and treatment of AATD in clinical practice.

5. Describe the pathophysiology and the epidemiology or Sarcoidosis; Understand the up-to-date methodology for diagnosis of Sarcoidosis; Review our current understanding of the treatments considered, including steroids, mineralocorticoid receptor agonists and treatments for advanced Sarcoidosis.

6. Discuss the diagnosis and classification of pulmonary hypertension according to the World Health Organization (WHO) clinical classification system; Outline an approach to rule out and appropriately manage chronic thromboembolic pulmonary hypertension (CTEPH), if present; Recognize the role of upfront, early combination and goal-oriented therapy for pulmonary arterial hypertension (PAH) and Risk Stratification; Describe the management of adverse events with PAH therapies and strategies to improve patient adherence.

7. Outline the epidemiology and risk factors for NTM-LD; Describe an approach to the diagnosis of NTM-LD; Discuss expert recommendations for the treatment of NTM-LD; Summarize the data on emerging therapies for NTM-LD.



 Continental Breakfast and Registration
8:00-8:10 Welcome Remarks
Franck Rahaghi, MD, MHS, FCCP


Asthma Frontiers: New Solutions To Old Problems
Dennis K. Ledford, MD, FAAAAI

 COPD – So Much is New!
Anas Hadeh, MD, FCCP

 Breaks and Exhibits
 Interstitial Lung Disease: Evolving Our Understanding of a Deadly Disease
Kevin Flaherty, MD, MS

 Alpha-1 Antitrypsin Deficiency: New Hope for Diagnosis and Treatment
Adam Wanner, MD

 Sarcoidosis: Update 2018
Franck Rahaghi, MD, MHS, FCCP

 Pulmonary Hypertension: Risk Stratification, A Guiding Light
Victor Test, MD

 Breaks and Exhibits
 Non-Tuberculosis Mycobacterial Lung Disease (NTM-LD) – New Horizons
Mehdi Mirsaeidi MD, MPH

 Closing Remarks
Franck Rahaghi, MD, MHS, FCCP

*Agenda subject to change



Kevin Flaherty, MD, MS
Professor in Pulmonary and Critical Care Medicine
University of Michigan
Ann Arbor, MI

Anas Hadeh, MD, FCCP
Director, Pulmonary and Critical Care Medicine Fellowship Program
Affiliate Assistant Professor of Clinical Biomedical Science
FAU Charles E. Schmidt College of Medicine
Cleveland Clinic Florida
Weston, FL

Mehdi Mirsaeidi MD, MPH
Director of UM and VA Sarcoidosis Programs
IRB Vice-Chairman, Miami VA Healthcare System
Division of Pulmonary, Critical Care,
Sleep and Allergy
Department of Medicine
University of Miami
Miller School of Medicine
Miami, FL

Franck Rahaghi, MD, MHS, FCCP
Director of Advanced Lung Disease Clinic
Director, Pulmonary Hypertension Clinic
Chairman, Dept. of Pulmonary and Critical Care
Cleveland Clinic Florida
Weston, FL

Adam Wanner, MD
Joseph Weintraub Professor of Medicine
Division of Pulmonary & Critical Care Medicine
University of Miami Miller School of Medicine
Scientific Director
Alpha-1 Foundation
Miami, FL

Dennis K. Ledford, MD, FAAAAI
Ellsworth and Mabel Simmons Professor of Allergy/Immunology
Past-President of Medical Faculty
Morsani COM, University of South Florida
Tampa, FL

Victor Test, MD
Chief, Division of Pulmonary & Critical Care Medicine
Director, Pulmonary Vascular Disease Program
Texas Tech University School of Medicine
Lubbock, TX

Planning Committee

Franck Rahaghi, MD, MHS, FCCP
Director of Advanced Lung Disease Clinic
Director, Pulmonary Hypertension Clinic
Chairman, Dept. of Pulmonary and Critical Care
Cleveland Clinic Florida
Weston, FL

Gregg Sherman, MD
Chief Medical Officer/Course Director
National Association for Continuing Education
Plantation, FL

Sheila Lucas, CWEP
Activity Director
National Association for Continuing Education

Plantation, FL

Sandy Bihlmeyer, M.Ed.
National Association for Continuing Education

Plantation, FL

Michelle Frisch, MPH, CHCP
National Association for Continuing Education

Plantation, FL

Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 6.0 contact hours of continuing education (which includes pharmacology hours).
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the accredited providers are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosure will be provided in the activity materials.
Commercial Support
This activity is supported, in part, by an educational grant from Bayer HealthCare Pharmaceuticals, Inc.; an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.; an educational grant from CSL Behring, LLC.; an educational grant from Grifols; an educational grant from Insmed; and an educational grant from Mallinckrodt Pharmaceuticals, LLC.